Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy
- 1 December 2000
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 14 (18), 2946-2948
- https://doi.org/10.1097/00002030-200012220-00020
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 2000
- Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin BAIDS, 1999
- Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA StudyAnnals of Internal Medicine, 1999
- Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1Nature Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 1998
- Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV DiseaseScience, 1997
- Leishmania and human immunodeficiency virus coinfection: the first 10 yearsClinical Microbiology Reviews, 1997
- Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patientsAmerican Journal Of Medicine, 1996
- Visceral Leishmaniasis (Kala-Azar) as an Opportunistic Infection in Patients Infected with the Human Immunodeficiency Virus in SpainClinical Infectious Diseases, 1989